CohBar, Inc. (CWBR)
Market Cap | 7.62M |
Revenue (ttm) | n/a |
Net Income (ttm) | -11.17M |
Shares Out | 2.91M |
EPS (ttm) | -3.82 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 7,765 |
Open | 2.58 |
Previous Close | 2.55 |
Day's Range | 2.56 - 2.71 |
52-Week Range | 1.50 - 10.50 |
Beta | 1.90 |
Analysts | Sell |
Price Target | 18.36 (+600.76%) |
Earnings Date | Mar 27, 2023 |
About CWBR
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CWBR stock is "Sell." The 12-month stock price forecast is $18.36, which is an increase of 600.76% from the latest price.
News

CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Conference call and webcast today at 5:00 p.m. ET, November 8, 2022 Conference call and webcast today at 5:00 p.m. ET, November 8, 2022

CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

7 Nasdaq Stocks to Sell Before They Die
As is typical of a bear market, the Nasdaq has led the other major indices lower over the past year. The tech-heavy index is down 28% over the past 12 months compared with a 17% decline in the S&P 500...

CohBar Announces Reverse Stock Split
MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its geno...

CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its geno...

CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
IND for CB5138-3 on track for second half of 2023

CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors
MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genom...

CohBar to Participate at Upcoming Conferences in June 2022
MENLO PARK, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genom...

CohBar to Present at the H.C. Wainwright Global Investment Conference
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome...

CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Conference call and webcast today at 5:00 p.m. ET, May 16, 2022 Conference call and webcast today at 5:00 p.m. ET, May 16, 2022

CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal
MENLO PARK, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encod...

CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Conference call and webcast at 5:00 p.m. ET today, March 29, 2022 Conference call and webcast at 5:00 p.m. ET today, March 29, 2022

CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

CohBar to Present at H.C. Wainwright BIOCONNECT Conference
MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genom...

CohBar Announces Changes to its Board of Directors and R&D Leadership
Founding board members transition to reconstituted Scientific Advisory Board

CohBar's CEO to Participate in Upcoming BIO Webinar
MENLO PARK, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten...

7 Penny Stocks With the Potential to 10X in 2022
The broader market looks expensive, but these penny stocks provide low-cost opportunities for considerable upside according to analysts. The post 7 Penny Stocks With the Potential to 10X in 2022 appea...

CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update
Company to host conference call at 5:00 p.m. ET

CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021
Company to host conference call at 5:00 p.m. ET Company to host conference call at 5:00 p.m. ET

CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
MENLO PARK, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic di...

CohBar Announces Proposed Public Offering of Common Stock and Warrants
MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic di...